Predominant envelope variable loop 2-specific and gp120-specific antibody-dependent cellular cytotoxicity antibody responses in acutely SIV-infected African green monkeys

[1]  D. Montefiori,et al.  Pathogenic Correlates of Simian Immunodeficiency Virus-Associated B Cell Dysfunction , 2017, Journal of Virology.

[2]  G. Fouda,et al.  Lessons learned from human HIV vaccine trials , 2017, Current opinion in HIV and AIDS.

[3]  R. O'Connell,et al.  Progress in HIV vaccine development , 2017, Human vaccines & immunotherapeutics.

[4]  D. Montefiori,et al.  Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk , 2017, Journal of Virology.

[5]  B. Haynes,et al.  The quest for an antibody‐based HIV vaccine , 2017, Immunological reviews.

[6]  S. Zolla-Pazner,et al.  Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits , 2016, Journal of Virology.

[7]  K. Dewar,et al.  Envelope-specific B-cell populations in African green monkeys chronically infected with simian immunodeficiency virus , 2016, Nature Communications.

[8]  Karen G. Dowell,et al.  Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition , 2016, Nature Medicine.

[9]  Jerome H. Kim,et al.  Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor , 2015, PloS one.

[10]  S. Zolla-Pazner,et al.  Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies , 2015, PloS one.

[11]  T. Kepler,et al.  Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies , 2015, Science.

[12]  H. Liao,et al.  Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys , 2015, Journal of Virology.

[13]  Zhiwei Chen,et al.  Simian Immunodeficiency Virus Infection Evades Vaccine-Elicited Antibody Responses to V2 Region , 2015, Journal of acquired immune deficiency syndromes.

[14]  Jerome H. Kim,et al.  Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection. , 2015, Annual review of medicine.

[15]  L. Xing,et al.  Trimeric HIV Env provides epitope occlusion mediated by hypervariable loops , 2014, Scientific Reports.

[16]  Jerome H. Kim,et al.  Cryptic Determinant of α4β7 Binding in the V2 Loop of HIV-1 gp120 , 2014, PloS one.

[17]  Jerome H. Kim,et al.  HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities , 2014, Journal of Virology.

[18]  Gary J. Nabel,et al.  Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination , 2014, Science Translational Medicine.

[19]  Steven H. Wu,et al.  Transient Compartmentalization of Simian Immunodeficiency Virus Variants in the Breast Milk of African Green Monkeys , 2013, Journal of Virology.

[20]  H. Liao,et al.  Lack of B Cell Dysfunction Is Associated with Functional, gp120-Dominant Antibody Responses in Breast Milk of Simian Immunodeficiency Virus-Infected African Green Monkeys , 2013, Journal of Virology.

[21]  Youdong Mao,et al.  A Twin-Cysteine Motif in the V2 Region of gp120 Is Associated with SIV Envelope Trimer Stabilization , 2013, PloS one.

[22]  Guido Ferrari,et al.  Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. , 2013, Immunity.

[23]  Allan C. deCamp,et al.  Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial , 2013, PloS one.

[24]  J. Lifson,et al.  Differential infection patterns of CD4+ T cells and lymphoid tissue viral burden distinguish progressive and nonprogressive lentiviral infections. , 2012, Blood.

[25]  Jerome H. Kim,et al.  The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. , 2012, AIDS research and human retroviruses.

[26]  J. Mascola,et al.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. , 2012, Immunity.

[27]  Tomer Hertz,et al.  Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env-V2 , 2012, Nature.

[28]  Jerome H. Kim,et al.  Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family , 2012, Journal of Virology.

[29]  Guido Ferrari,et al.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial. , 2012, The New England journal of medicine.

[30]  G. Silvestri,et al.  Natural SIV Hosts: Showing AIDS the Door , 2012, Science.

[31]  T. Kepler,et al.  Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated , 2011, The Journal of experimental medicine.

[32]  Surender Khurana,et al.  Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin , 2011, Proceedings of the National Academy of Sciences.

[33]  J. Kappes,et al.  High‐throughput quantitative analysis of HIV‐1 and SIV‐specific ADCC‐mediating antibody responses , 2011, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[34]  J. Kappes,et al.  An HIV-1 gp120 Envelope Human Monoclonal Antibody That Recognizes a C1 Conformational Epitope Mediates Potent Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity and Defines a Common ADCC Epitope in Human HIV-1 Serum , 2011, Journal of Virology.

[35]  K. Reimann,et al.  Blocking of α4β7 Gut-Homing Integrin during Acute Infection Leads to Decreased Plasma and Gastrointestinal Tissue Viral Loads in Simian Immunodeficiency Virus-Infected Rhesus Macaques , 2011, The Journal of Immunology.

[36]  Brian T. Foley,et al.  HIV Sequence Compendium 2018 , 2010 .

[37]  K. Taylor,et al.  Structural Comparison of HIV-1 Envelope Spikes with and without the V1/V2 Loop , 2010, Journal of Virology.

[38]  H. Ding,et al.  Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. , 2010, Virology.

[39]  G. Learn,et al.  Genetic Identity and Biological Phenotype of a Transmitted/Founder Virus Representative of Nonpathogenic Simian Immunodeficiency Virus Infection in African Green Monkeys , 2010, Journal of Virology.

[40]  O. Gascuel,et al.  SeaView version 4: A multiplatform graphical user interface for sequence alignment and phylogenetic tree building. , 2010, Molecular biology and evolution.

[41]  D. Montefiori,et al.  Effect of B-Cell Depletion on Viral Replication and Clinical Outcome of Simian Immunodeficiency Virus Infection in a Natural Host , 2009, Journal of Virology.

[42]  J. McCune,et al.  Gag p27-Specific B- and T-Cell Responses in Simian Immunodeficiency Virus SIVagm-Infected African Green Monkeys , 2008, Journal of Virology.

[43]  Vicki C. Ashley,et al.  Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia , 2008, Journal of Virology.

[44]  R. Gelman,et al.  Potent Simian Immunodeficiency Virus-Specific Cellular Immune Responses in the Breast Milk of Simian Immunodeficiency Virus-Infected, Lactating Rhesus Monkeys1 , 2008, The Journal of Immunology.

[45]  Stephen D Fuller,et al.  Cryo-Electron Tomographic Structure of an Immunodeficiency Virus Envelope Complex In Situ , 2006, PLoS pathogens.

[46]  Don C. Wiley,et al.  Structure of an unliganded simian immunodeficiency virus gp120 core , 2005, Nature.

[47]  J. Clements,et al.  Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. , 2002, AIDS research and human retroviruses.

[48]  J. Robinson,et al.  Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain. , 2001, Virology.

[49]  E. Fenyö,et al.  Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region. , 2001, AIDS research and human retroviruses.

[50]  L. Stamatatos,et al.  V2 Loop Glycosylation of the Human Immunodeficiency Virus Type 1 SF162 Envelope Facilitates Interaction of This Protein with CD4 and CCR5 Receptors and Protects the Virus from Neutralization by Anti-V3 Loop and Anti-CD4 Binding Site Antibodies , 2000, Journal of Virology.

[51]  A. Trkola,et al.  A Cell Line-Based Neutralization Assay for Primary Human Immunodeficiency Virus Type 1 Isolates That Use either the CCR5 or the CXCR4 Coreceptor , 1999, Journal of Virology.

[52]  D. Roos,et al.  FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype , 1997 .

[53]  R. Kurth,et al.  Lack of dichotomy between virus load of peripheral blood and lymph nodes during long-term simian immunodeficiency virus infection of African green monkeys. , 1996, Virology.

[54]  Division on Earth.  Guide for the Care and Use of Laboratory Animals , 1996 .

[55]  C. Chappey,et al.  Simian immunodeficiency viruses from central and western Africa: evidence for a new species-specific lentivirus in tantalus monkeys , 1993, Journal of virology.

[56]  R. Kurth,et al.  Development of vivo of genetic variability of simian immunodeficiency virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[57]  R. Kurth,et al.  Immunological studies of the basis for the apathogenicity of simian immunodeficiency virus from African green monkeys. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Lloyd H. Michael,et al.  The Guide for the Care and Use of Laboratory Animals. , 2016, ILAR journal.

[59]  D. Roos,et al.  Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. , 1997, Blood.